Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.

Targeted therapies are efficient in the context of oncogenic driver mutations. Epidermal growth factor receptor (EGFR)-mutant lung cancers represent a distinct subset of non-small-cell lung cancer ...